TipRanks on MSN3mon
Roche announces PADOVA study misses statistical significancePrasinezumab showed potential clinical efficacy in the primary endpoint of time to confirmed motor progression with a hazard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback